Pharmacovigilance companies exist to protect patients — catching drug safety signals before they become crises, filing Individual Case Safety Reports (ICSRs) on time, and keeping regulators informed. But the sheer volume of data flowing through a modern PV operation can overwhelm even well-staffed teams, particularly as biologics, biosimilars, and combination therapies multiply the complexity of signal detection.
Virtual assistants (VAs) are increasingly positioned as a force multiplier for pharmacovigilance operations, absorbing the administrative and data-processing load so that qualified safety scientists can concentrate on case assessment and signal evaluation.
The Volume Problem in Modern Pharmacovigilance
The FDA's MedWatch system received over 2.3 million adverse event reports in 2023, a figure that has grown steadily year over year as electronic reporting has become more accessible. For pharmacovigilance companies handling outsourced PV services for multiple sponsors, that volume translates into relentless pressure on every team member from data entry staff to senior safety physicians.
The European Medicines Agency similarly reported rising ICSR submissions through EudraVigilance, with expedited 15-day reports requiring immediate triage the moment they arrive. Missing a regulatory deadline — even by a day — carries significant consequences for both the PV firm and the sponsor.
How VAs Support Pharmacovigilance Workflows
Virtual assistants with training in medical terminology and pharmaceutical documentation standards can be deployed across multiple PV workflow layers:
Initial case intake and triage support. VAs receive incoming adverse event narratives from call centers, patient portals, and healthcare providers, then categorize them by seriousness and expectedness criteria before routing to safety scientists. This first-pass triage reduces the manual sorting burden on licensed professionals.
Data entry and ICSR preparation. Entering structured case data into safety databases like Argus or ARISg is time-consuming but rule-bound. VAs handle data entry, narrative transcription, and completeness checks — flagging missing follow-up information so scientists can request it without breaking stride on case assessment.
Regulatory submission tracking. VAs maintain submission calendars, track outstanding 15-day and periodic reports, and coordinate with regulatory affairs counterparts to ensure no deadline slips. They also manage follow-up correspondence with healthcare professionals who submitted initial reports.
Literature monitoring support. Systematic literature searches for potential cases in published literature are a regulatory requirement under ICH E2F guidance. VAs conduct structured PubMed and EMBASE searches, compile abstracts, and flag potentially relevant articles for medical review — turning a multi-hour task into a routine delegation.
Scalability as a Strategic Asset
One of the clearest advantages of VA support for pharmacovigilance companies is scalability. PV workloads spike around product launches, safety label updates, and post-marketing commitments. Hiring permanent staff to cover peak periods is expensive and inefficient; VAs allow firms to scale capacity in direct proportion to case volume.
According to a Deloitte Life Sciences analysis, outsourced pharmacovigilance services are among the fastest-growing segments in pharmaceutical outsourcing, with mid-tier PV firms under particular pressure to demonstrate cost efficiency without compromising quality. VAs represent a practical lever for achieving that balance.
Building a VA-Enabled PV Operation
Successful integration typically starts with non-safety-critical workflows — literature monitoring, case intake documentation, and submission tracking — before expanding to case preparation support as the VA team demonstrates competency and reliability. Clear SOPs and quality checks are essential.
Firms evaluating VA partnerships should prioritize providers familiar with pharmaceutical regulatory environments. Stealth Agents offers virtual assistants with experience supporting life sciences and healthcare clients, trained in the documentation standards and communication protocols that pharmacovigilance operations depend on.
For PV companies facing rising case volumes and flat headcount budgets, that kind of targeted support can mean the difference between meeting every regulatory deadline and falling behind.
Sources
- FDA MedWatch, Adverse Event Reporting System (FAERS) Annual Summary, 2023
- European Medicines Agency, EudraVigilance Annual Report, 2023
- Deloitte Life Sciences, Outsourcing in Pharmacovigilance: Trends and Benchmarks, 2024